IRMD vs. NARI, WRBY, LIVN, TMDX, ENOV, TNDM, CNMD, SLNO, INMD, and RXST
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include Inari Medical (NARI), Warby Parker (WRBY), LivaNova (LIVN), TransMedics Group (TMDX), Enovis (ENOV), Tandem Diabetes Care (TNDM), CONMED (CNMD), Soleno Therapeutics (SLNO), InMode (INMD), and RxSight (RXST). These companies are all part of the "medical equipment" industry.
Iradimed vs.
Iradimed (NASDAQ:IRMD) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
Iradimed received 186 more outperform votes than Inari Medical when rated by MarketBeat users. Likewise, 64.78% of users gave Iradimed an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
In the previous week, Inari Medical had 49 more articles in the media than Iradimed. MarketBeat recorded 52 mentions for Inari Medical and 3 mentions for Iradimed. Iradimed's average media sentiment score of 1.08 beat Inari Medical's score of 0.40 indicating that Iradimed is being referred to more favorably in the media.
92.3% of Iradimed shares are held by institutional investors. Comparatively, 91.0% of Inari Medical shares are held by institutional investors. 37.1% of Iradimed shares are held by company insiders. Comparatively, 10.6% of Inari Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Iradimed has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Inari Medical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Iradimed currently has a consensus target price of $60.00, suggesting a potential downside of 0.02%. Inari Medical has a consensus target price of $68.00, suggesting a potential downside of 14.23%. Given Iradimed's stronger consensus rating and higher possible upside, analysts clearly believe Iradimed is more favorable than Inari Medical.
Iradimed has a net margin of 26.12% compared to Inari Medical's net margin of -13.68%. Iradimed's return on equity of 23.99% beat Inari Medical's return on equity.
Iradimed has higher earnings, but lower revenue than Inari Medical. Inari Medical is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Summary
Iradimed beats Inari Medical on 15 of the 18 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
This page (NASDAQ:IRMD) was last updated on 1/10/2025 by MarketBeat.com Staff
Free IRMD Stock Alerts